SITC WORLD IMMUNOTHERAPY COUNCIL'S YOUNG INVESTIGATOR SYMPOSIUM
Program Purpose
The Society for Immunotherapy of Cancer and the World Immunotherapy Council (WIC) are dedicated to advancing cancer immunotherapy and, likewise, the future leaders of the field. This program will provide the opportunity for young scientists and future leaders from throughout the world to interact, fulfilling the World Immunotherapy Council’s mission to facilitate rapid development and global dissemination of cancer immunotherapies through scientific exchange.
The young investigators, each chosen for exemplary work in the field of cancer immunotherapy, will contribute insight and perspectives into present and future issues, challenges, and improvements as cancer immunotherapy is integrated into mainstream cancer treatment. This program and its participants will ultimately highlight worldwide initiatives in cancer immunotherapy and facilitate scientific exchange and networking between today’s and tomorrow’s leaders. Additionally, this forum will provide a unique opportunity to showcase the world’s young, talented scientists and provide an opportunity for knowledge exchange and networking for these selected representatives.
Intended Audience
The target audience for this program consists of individuals from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals who wish to learn more about the future of cancer immunotherapy research across the globe.
The Society for Immunotherapy of Cancer and the World Immunotherapy Council (WIC) are dedicated to advancing cancer immunotherapy and, likewise, the future leaders of the field. This program will provide the opportunity for young scientists and future leaders from throughout the world to interact, fulfilling the World Immunotherapy Council’s mission to facilitate rapid development and global dissemination of cancer immunotherapies through scientific exchange.
The young investigators, each chosen for exemplary work in the field of cancer immunotherapy, will contribute insight and perspectives into present and future issues, challenges, and improvements as cancer immunotherapy is integrated into mainstream cancer treatment. This program and its participants will ultimately highlight worldwide initiatives in cancer immunotherapy and facilitate scientific exchange and networking between today’s and tomorrow’s leaders. Additionally, this forum will provide a unique opportunity to showcase the world’s young, talented scientists and provide an opportunity for knowledge exchange and networking for these selected representatives.
Intended Audience
The target audience for this program consists of individuals from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals who wish to learn more about the future of cancer immunotherapy research across the globe.
Educational Objectives
Upon completion of this meeting, participants will be able to:
|
Nominated CCIC Representatives
1st - NOV 4, 2015 - Julie Nielsen, BC Cancer Agency
Presentation Title: "Toward personalized immunotherapy for lymphoma: Identification of common driver mutations recognized by patient T cells" |
2nd - NOV 8, 2017 - Sarah Crome, Princess Margaret Cancer Center
Presentation Title: "A novel innate lymphoid cell population regulates tumor-associated T cells" |
3rd - NOV 6, 2019 - Diana Canals, University of British Columbia
Presentation Title: "Podocalyxin is a Therapeutic Target in Carcinoma" |
4th - NOV 10, 2021 - Adam Nelson, Dalhousie University
Presentation Title: "Combination of NKT cell immunotherapy and oncolytic vesicular stomatitis virus expressing FAST proteins clears metastatic triple negative breast cancer" |
5 thNOV 1, 2023 - Anirban Das, The Hospital for Sick Children
Presentation Title: "Combined immunotherapy improves outcome for replication repair deficient (RRD) high grade glioma failing anti-PD1 monotherapy: a report from the international RRD Consortium" |